Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tamoxifen. Found 27 abstracts

no pagination
Chakraborty AK, Mehra R, Digiovanna MP. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer research. 2015 Mar;35(3):1243-50.
Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC. Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. Journal of Clinical Oncology. 2012 Jun;30(18):2218-26.   PMCID: PMC3397718 [Available on 2013/6/20]
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Murphy C, Anderson PR, Li TY, Bleicher RJ, Sigurdson ER, Goldstein LJ, Swaby R, Denlinger C, Dushkin H, Nicolaou N, Freedman GM. IMPACT OF THE RADIATION BOOST ON OUTCOMES AFTER BREAST-CONSERVING SURGERY AND RADIATION. International Journal of Radiation Oncology Biology Physics. 2011 Sep;81(1):69-76.   PMCID: PMC2992091
Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, MacDonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast Cancer Risk Reduction. Journal of the National Comprehensive Cancer Network. 2010 Oct;8(10):1112-46.   PMCID: not NIH funded
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Som G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast Cancer: Noninvasive and Special Situations. Journal of the National Comprehensive Cancer Network. 2010 Oct;8(10):1182-207.   PMCID: not NIH funded
Ropka ME, Keim J, Philbrick JT. Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. 2010 Jun;28(18):3090-5.   PMCID: PMC2903338
Lewis-Wambi JS, Swaby R, Kim H, Jordan VC. Potential of L-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 2009 Mar;114(1-2):33-9.   PMCID: PMC28689080
Maximov PY, Lewis-Wambi JS, Jordan VC. The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Current Signal Transduction Therapy. 2009 May;4(2):88-102.   PMCID: PMC2757321
Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC. Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer. Journal of the National Comprehensive Cancer Network. 2009 Feb;7(2):115-21.   PMCID: No NIH
Jordan VC. Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer. Geburtshilfe Und Frauenheilkunde. 2007 May;67(5):443-50.
Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007 Jan;72(1):7-25.
Jordan VC, Lewis-Wambi J, Kim H, Cunliffe H, Ariazi E, Sharma CG, Shupp HA, Swaby R. Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast. 2007 Dec;16:S105-S113.
Buchholz TA, Theriault RL, Niland JC, Hughes ME, Ottesen R, Edge SB, Bookman MA, Weeks JC. The use of radiation as a component of breast conservation therapy in national comprehensive cancer network centers. Journal of Clinical Oncology. 2006 Jan 20;24(3):361-9.
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. International journal of cancer. 2006 May;118(9):2281-4.
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, Haybittle JL, Davies C, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Forbes JF, Wilcken N, Gnant M, Jakesz R, Ploner M, Yosef HM, Focan C, Lobelle JP, Peek U, Oates GD, Powell J, Durand M, Mauriac L, Di Leo A, Dolci S, Piccart MJ, Masood MB, Parker D, Price JJ, Hupperets P, Jackson S, Ragaz J, Berry D, Broadwater G, Cirrincione C, Muss H, Norton L, Weiss RB, Abu-Zahra HT, Portnoj SM, Baum M, Cuzick J, Houghton J, Riley D, Gordon NH, Davis HL, Beatrice A, Mihura J, Naja A, Lehingue Y, Romestaing P, Dubois JB, Delozier T, Mace-Lesec'h J, Rambert P, Andrysek O, Barkmanova J, Owen JR, Meier P, Howell A, Ribeiro GC, Swindell R, Alison R, Boreham J, Clarke M, Collins R, Darby S, Elphinstone P, Evans V, Godwin J, Gray R, Harwood C, Hicks C, James S, MacKinnon E, McGale !P, McHugh T, Mead G, Peto R, Wang Y, Albano J, de Oliveira CF, Gervasio H, Gordilho J, Johansen H, Mouridsen HT, Gelman RS, Harris JR, Henderson IC, Shapiro CL, Andersen KW, Axelsson CK, Blichert-Toft M, Moller S, Overgaard J, Overgaard M, Rose C, Cartensen B, Palshof T, Trampisch HJ, Dalesio O, de Vries EG, Rodenhuis S, van Tinteren H, Comis RL, Davidson NE, Robert N, Sledge G, Tormey DC, Wood W, Cameron D, Chetty U, Forrest P, Jack W, Rossbach J, Klijn JG, Treurniet-Donker AD, van Putten WL, Costa A, Veronesi U, Bartelink H, Duchateau L, Legrand C, Sylvester R, van der Hage JA, van de Velde CJ, Cunningham MP, Catalano R, Creech RH, Bonneterre J, Fargeot P, Fumoleau P, Kerbrat P, Namer M, Jonat W, Kaufmann M, Schumacher M, von Minckwitz G, Bastert G, Rauschecker H, Sauer R, Sauerbrei W, Schauer A, de Schryver A, Vakaet L, Belfiglio M, Nicolucci A, Pellegrini F, Sacco M, Valentini M, McArdle CS, Smith DC, Galligioni E, Bocc ardo F, Rubagotti A, Dent DM, Gudgeon CA, Hacking A, Erazo A, Medina JY, Izuo M, Morishita Y, Takei H, Fentiman IS, Hayward JL, Rubens RD, Skilton D, Graeff H, Janicke F, Meisner C, Scheurlen H, von Fournier D, Dafni U, Fountzilas G, Klefstrom P, Blomqvist C, Saarto T, Margreiter R, Asselain B, Salmon RJ, Vilcoq JR, Arriagada R, Hill C, Laplanche A, Le MG, Spielmann M, Bruzzi P, Montanaro E, Rosso R, Sertoli MR, Venturini M, Amadori D, Benraadt J, Kooi M, van de Velde AO, van Dongen JA, Vermorken JB, Castiglione M, Cavalli F, Coates A, Collins J, Forbes J, Gelber RD, Goldhirsch A, Lindtner J, Price KN, Rudenstam CM, Senn HJ, Bliss JM, Chilvers CE, Coombes RC, Hall E, Marty M, Borovik R, Brufman G, Hayat H, Robinson E, Wigler N, Bonadonna G, Camerini T, De Palo G, Del Vecchio M, Formelli F, Valagussa P, Martoni A, Pannuti F, Cocconi G, Colozza A, Camisa R, Aogi K, Takashima S, Ikeda T, Inokuchi K, Sawa K, Sonoo H, Korzeniowski S, Skolyszewski J, Ogawa M, Yamashita J, Bonte J, Christiaens R, Paridaens R, Van den Boegart W, Martin P, Romain S, Hakes T, Hudis CA, Wittes R, Giokas G, Kondylis D, Lissaios B, de la Huerta R, Sainz MG, Altemus R, Cowan K, Danforth D, Lichter A, Lippman M, O'Shaughnessy J, Pierce LJ, Steinberg S, Venzon D, Zujewski J, Paradiso A, De Lena M, Schittulli F, Myles JD, Pater JL, Pritchard KI, Anderson S, Bass G, Brown A, Bryant J, Costantino J, Dignam J, Fisher B, Redmond C, Wieand S, Wolmark N, Jackson IM, Palmer MK, Ingle JN, Suman VJ, Bengtsson NO, Jonsson H, Larsson LG, Lythgoe JP, Kissin M, Erikstein B, Hannisdal E, Jacobsen AB, Varhaug JE, Gundersen S, Hauer-Jensen M, Host H, Nissen-Meyer R, Blamey RW, Mitchell AK, Morgan DA, Robertson JF, Di Palma M, Mathe G, Misse! t JL, Clark RM, Levine M, Morimoto K, Takatsuka Y, Cross ley E, Harris A, Talbot D, Taylor M, di Blasio B, Ivanov V, Semiglazov V, Brockschmidt J, Cooper MR, Ueo H, Falkson CI, A'Hern R, Ashley S, Powles TJ, Smith IE, Yarnold JR, Gazet JC, Cocoran N, Deshpande N, di Martino L, Douglas P, Lindtner A, Notter G, Bryant AJ, Ewing GH, Firth LA, Krushen-Kosloski JL, Foster L, George WD, Stewart HJ, Stroner P, Malmstrom P, Moller TR, Ryden S, Tengrup I, Tennvall-Nittby L, Carstenssen J, Dufmats M, Hatschek T, Nordenskjold B, Soderberg M, Carpenter JT, Albain K, Crowley J, Green S, Martino S, Osborne CK, Ravdin PM, Glas U, Johansson U, Rutqvist LE, Singnomklao T, Wallgren A, Maibach R, Thurlimann B, Brenner H, Hercbergs A, Yoshimoto M, DeBoer G, Paterson AH, Meakin JW, Panzarella T, Shan Y, Shao YF, Wang X, Zhao DB, Chen ZM, Pan HC, Bahi J, Reid M, Spittle M, Deutsch GP, Senanayake F, Kwong DL, Bianco AR, Carlomagno C, De Laurentiis M, De Placido S, Buzdar AU, Smith T, Bergh J, Holmberg L, Liljegren G, Nilsson J, Seifert M, Sevelda P, Zielinsky CC, Buchanan RB, Cross M, Royle GT, Dunn JA, Hills RK, Lee M, Morrison JM, Spooner D, Litton A, Chlebowski RT, Caffier HG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England). 2005 May 14;365(9472):1687-717.
Bookman MA. Is there still a role for hormonal therapy?. International Journal of Gynecological Cancer. 2005 Nov 03;15:291-7.
Jordan VC. In postmenopausal women with breast cancer, switching to exemestane increased disease-free survival compared to continuing tamoxifen. Evidence-based Obstetrics and Gynecology. 2005 Jan;7(2):103-4.
Jordan VC, Lewis JS, Osipo C, Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast. 2005 Dec;14(6):624-30.
Park WC, Liu H, Schafer JM, Jordan VC. Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells. International Journal of Oncology. 2005 Nov;27(5):1459-66.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tamoxifen

tamoxifen breast cancer raloxifene randomized-trial BOWEL PROJECT P-1 receptor prevention Breast cancer SURGICAL ADJUVANT BREAST POSTMENOPAUSAL WOMEN apoptosis ATHYMIC MICE cancer radiotherapy aromatase inhibitors surgical adjuvant breast women estrogen receptor survival risk reduction MAMMARY-CARCINOMA MODEL RANDOMIZED-TRIAL NCCN Guidelines NCCN Clinical Practice Guidelines endocrine therapy THERAPY assay recurrence AROMATASE INHIBITOR LETROZOLE multicenter trial postmenopausal women tamoxifen therapy TAMOXIFEN randomized controlled-trial irradiation Tumor Cell Line LCIS surgical clips ANTIAPOPTOTIC rt-pcr assay gene-expression analysis BRCA2 lumpectomy dietary modification trial combination clinical-trial melphalan breast-cancer 4-hydroxyandrostenedione Aromatase inhibitors risk 2000 wble b-p189 SERM BCRA1 prognosis subunit estrogen-receptor modulators cyto-toxicity Female validation RANDOMIZED CLINICAL-TRIAL Tamoxifen 1987 arlson me-journal of chronic diseases-v40-p373 breast carcinoma Apoptosis unknown susceptibility genes oestrogen receptor epithelial ovarian-cancer noninvasive breast BRCA1 breast neoplasms Trastuzumab estrogen-receptor status ovarian cancer oestrogen action exemestane ovarian-cancer prophylactic mastectomy TAMOXIFEN RESISTANCE pagets-disease Estrogen Antagonists trastuzumab (Herceptin) anastrozole RALOXIFENE antihormonal therapy Oncology fulvestrant (Faslodex) ANTI-TUMOUR AGENT gene array analysis ADJUVANT BREAST LONG-TERM risk assessment radiation therapy FIRST-LINE perceptions estrogen SMALL-MOLECULE INHIBITOR phase-i signature estrogen replacement therapy oophorectomy mutation carriers Breast Neoplasms phase-ii trial ESTROGEN-RECEPTOR-ALPHA 474 TAMOXIFEN ICI 46 pathology 474 tamoxifen ici 46 older women 474 ICI 46 antihormone resistance carcinomas carcinoma-in-situ hormonal-therapy conserving surgery htert bilateral prophylactic mastectomy estrogen receptor (ER) estrogen deprivation ANTIESTROGENS menopausal term chemotherapy update cell-proliferation steroid-receptors therapy lobular carcinoma in situ telomerase drug effects modulation carcinoma in-situ american society ErbB-2 Receptor athymic mice american-joint-committee reducing salpingo-oophorectomy Radiation boost tumors Radiation therapy deprivation adjuvant therapy hormone therapy Her2 bone-mineral density PHASE-II TRIAL elements CLINICAL-TRIAL
Last updated on Sunday, July 05, 2020